Labcorp(LH)与肿瘤临床试验联盟达成全美战略合作扩大结直肠癌基因检测范围

金吾财讯05-29

金吾财讯 | Labcorp(LH)宣布，已与肿瘤临床试验联盟达成一项全美战略合作。Labcorp将作为独家基因检测提供商，全面支持一项针对新确诊结直肠癌(CRC)患者及其高危亲属的全国性、多中心大型临床试验。据悉，该研究项目由美国国家卫生研究院(NIH)下属的美国国家癌症研究所(NCI)全额资助，由肿瘤临床试验联盟负责主导和实施。其招募网络广泛，涵盖了全美及波多黎各地区的学术医学中心、社区肿瘤医疗系统以及NCI指定的癌症中心。作为本项全国性试验的独家技术支持方，Labcorp将依托其旗下的Invitae基因检测平台，凭借其覆盖全美的实验室网络规模和深厚的伴随诊断学术积累，为所有参与机构提供高质量的生殖系基因检测与多基因联合检测服务。

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/2639102624?lang=zh_CN&edition=full","thumbnail":"https://static.szfiu.com/news/20250107/YjU2YzAxODc0YzFlOTM1Nzk3MTU1NDIzZDRjODY4MTE1MzM5MTg2.png","is_english":false,"pubTime":"2026-05-29 19:29","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2639102624","market":"nz","top_or_hot":-1,"title":"Labcorp(LH)与肿瘤临床试验联盟达成全美战略合作 扩大结直肠癌基因检测范围","media":"金吾财讯","content":"<html><body><p>金吾财讯 | Labcorp(LH)宣布，已与肿瘤临床试验联盟达成一项全美战略合作。Labcorp将作为独家基因检测提供商，全面支持一项针对新确诊结直肠癌(CRC)患者及其高危亲属的全国性、多中心大型临床试验。据悉，该研究项目由美国国家卫生研究院(NIH)下属的美国国家癌症研究所(NCI)全额资助，由肿瘤临床试验联盟负责主导和实施。其招募网络广泛，涵盖了全美及波多黎各地区的学术医学中心、社区肿瘤医疗系统以及NCI指定的癌症中心。作为本项全国性试验的独家技术支持方，Labcorp将依托其旗下的Invitae基因检测平台，凭借其覆盖全美的实验室网络规模和深厚的伴随诊断学术积累，为所有参与机构提供高质量的生殖系基因检测与多基因联合检测服务。</p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Labcorp(LH)与肿瘤临床试验联盟达成全美战略合作 扩大结直肠癌基因检测范围</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nLabcorp(LH)与肿瘤临床试验联盟达成全美战略合作 扩大结直肠癌基因检测范围\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-05-29 19:29 北京时间&nbsp;&nbsp;&nbsp;<a href=300983><strong>金吾财讯</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>金吾财讯 | Labcorp(LH)宣布，已与肿瘤临床试验联盟达成一项全美战略合作。Labcorp将作为独家基因检测提供商，全面支持一项针对新确诊结直肠癌(CRC)患者及其高危亲属的全国性、多中心大型临床试验。据悉，该研究项目由美国国家卫生研究院(NIH)下属的美国国家癌症研究所(NCI)全额资助，由肿瘤临床试验联盟负责主导和实施。其招募网络广泛，涵盖了全美及波多黎各地区的学术医学中心、社区肿瘤...</p>\n\n<a href=\"300983\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LU0742534661.SGD","symbol_name":"Fidelity America A-SGD (hedged)","start_time":0,"source_url":"300983","article_id":"2639102624","we_media_id":"1086022552","thumbnails":["https://static.szfiu.com/news/20250107/YjU2YzAxODc0YzFlOTM1Nzk3MTU1NDIzZDRjODY4MTE1MzM5MTg2.png"],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2639102624","pubTimestamp":1780054196,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"金吾财讯","introduction":"「金吾财讯」以精准用户需求为切入点，打造一站式港美股投资细分领域品牌。依托战略合作伙伴凤凰网财经，将港美股内容传播到全球华人圈。","home_visible":1,"id":"1086022552","head_image":"https://static.tigerbbs.com/19a93586c3b023ec6ebfed568990555c"},"summary":"Labcorp将作为独家基因检测提供商，全面支持一项针对新确诊结直肠癌患者及其高危亲属的全国性、多中心大型临床试验。作为本项全国性试验的独家技术支持方，Labcorp将依托其旗下的Invitae基因检测平台，凭借其覆盖全美的实验室网络规模和深厚的伴随诊断学术积累，为所有参与机构提供高质量的生殖系基因检测与多基因联合检测服务。","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"zh","relate_stocks":{"LU0742534661.SGD":"Fidelity America A-SGD (hedged)","LU0006061336.USD":"Blackrock US Small and MidCap Opportunities A2 USD","LU2237438978.USD":"Amundi Funds US Pioneer A2 (C) USD","LH":"徕博科","BK4196":"保健护理服务","LU0048573561.USD":"FIDELITY AMERICA \"A\" (USD) INC","BK4588":"碎股","LU1059921491.USD":"NORDEA 1 GLOBAL STABLE EQUITY \"HB\" (USDHDG) ACC","LU0251131958.USD":"FIDELITY AMERICA \"A\" (USD) ACC","LU0251142724.SGD":"Fidelity America A-SGD","BK4550":"红杉资本持仓","BK4585":"ETF&股票定投概念"},"translate_title":"Labcorp (LH) and Cancer Clinical Trials Alliance reach U.S. -wide strategic cooperation to expand the scope of colorectal cancer genetic testing","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"LH":1.5},"content_text":"金吾财讯 | Labcorp(LH)宣布，已与肿瘤临床试验联盟达成一项全美战略合作。Labcorp将作为独家基因检测提供商，全面支持一项针对新确诊结直肠癌(CRC)患者及其高危亲属的全国性、多中心大型临床试验。据悉，该研究项目由美国国家卫生研究院(NIH)下属的美国国家癌症研究所(NCI)全额资助，由肿瘤临床试验联盟负责主导和实施。其招募网络广泛，涵盖了全美及波多黎各地区的学术医学中心、社区肿瘤医疗系统以及NCI指定的癌症中心。作为本项全国性试验的独家技术支持方，Labcorp将依托其旗下的Invitae基因检测平台，凭借其覆盖全美的实验室网络规模和深厚的伴随诊断学术积累，为所有参与机构提供高质量的生殖系基因检测与多基因联合检测服务。","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"corporation","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.43.1","shortVersion":"4.43.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2639102624","isCrawlerRequest":true}

Labcorp(LH)与肿瘤临床试验联盟达成全美战略合作 扩大结直肠癌基因检测范围

精彩评论

Labcorp(LH)与肿瘤临床试验联盟达成全美战略合作扩大结直肠癌基因检测范围